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Abstract: Low-grade gliomas (LGG) are infiltrative primary brain tumors that in 70% of the cases
undergo anaplastic transformation, deeply affecting prognosis. However, the timing of progression
is heterogeneous. Recently, the tumor microenvironment (TME) has gained much attention either
as prognostic factor or therapeutic target. Through the release of extracellular vesicles, the TME
contributes to tumor progression by transferring bioactive molecules such as microRNA. The aim of
the study was to take advantage of glioma-associated stem cells (GASC), an in vitro model of the
glioma microenvironment endowed with a prognostic significance, and their released exosomes,
to investigate the possible role of exosome miRNAs in favoring the anaplastic transformation of
LGG. Therefore, by deep sequencing, we analyzed and compared the miRNA profile of GASC and
exosomes obtained from LGG patients characterized by different prognosis. Results showed that
exosomes presented a different signature, when compared to their cellular counterpart and that,
although sharing several miRNAs, exosomes of patients with a bad prognosis, selectively expressed
some miRNAs possibly responsible for the more aggressive phenotype. These findings get insights
into the value of TME and exosomes as potential biomarkers for precision medicine approaches
aimed at improving LGG prognostic stratification and therapeutic strategies.
Keywords: exosomes; tumor microenvironment; microRNA; low-grade gliomas; stratification criteria
1. Introduction
Adult diffuse low-grade gliomas (LGG) are classified and graded based on histological and
molecular parameters according to the World Health Organization (WHO) classification of brain
tumors [1]. Although glioblastoma (WHO grade IV) remains the most aggressive and deadliest tumor
of the central nervous system, with a median survival time of 12.2–18.2 months [2], WHO grade
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II gliomas also represent a clinical challenge, due to their highly variable behavior [3,4]. Indeed,
some LGG remain indolent for years, while others rapidly progress to glioblastoma, therefore,
the survival of LGG patients ranges from 15 years to 1 year [3,4]. Comprehensive genome studies have
contributed to a better prognostic stratification of lower grade glioma [5–8]. Specifically, diffuse gliomas
isocitrate dehydrogenase (IDH) wildtype are characterized by the worst prognosis, oligodendrogliomas,
IDH mutant, and 1p/19q co-deleted, by the best while diffuse astrocytoma IDH mutant by an intermediate
prognosis [5–8]. However, even inside the same molecular group, there are differences in both risk and
timing of malignant transformation. This makes it difficult to choose the therapeutic strategy, aimed at
aggressively treating patients with a potentially more malignant neoplasm and avoiding adjuvant
therapies to patients who could only progress after many years [3,4,9]. In fact, chemotherapy and
especially radiotherapy, the only available adjuvant treatments, are burdened by severe side effects,
such as the risk of late cognitive defects following radiotherapy. To refine the therapeutic approach
towards personalized medicine, it is increasingly important to understand the molecular mechanisms
driving the malignant evolution of LGG. To this aim, Bai et at. compared the genomic landscape of
41 WHO grade II IDH mutant astrocytomas to their higher-grade, progressed counterpart. Integrated
genomic analyses, including whole-exome sequencing and copy number, gene expression, and DNA
methylation profiling, showed, in the progressed sample, the activation of the MYC and RTK-RAS-PI3K
pathways and upregulation of genes involved in the cell cycle transition, such as FOXM1 and E2F2,
and the epigenetic silencing of genes related to Polycomb repressive complex 2 [10].
However, increasing evidence shows that cancer progression is driven, not only by genetic alterations,
but also by the crosstalk established by tumor cells and the surrounding microenvironment [11–14].
In gliomas, the tumor microenvironment (TME) consists of non-tumor cells, such as endothelial
cells, tumor-associated macrophages (TAMs), microglia, resident astrocytes, extracellular matrix
components, proteins, and secreted molecules, all acting in the intercellular communication with tumor
cells, thus modulating disease progression [15–17].
Important players of the potent cross talk between cancer cells and the TME are exosomes,
small extracellular vesicles, with a diameter ranging between 50 to 150 nm [18–20]. They originate in the
multivesicular body compartment of the endoplasmic reticulum and are released into the extracellular
space and in the body fluids from many cell types [21]. After release, exosomes are internalized by
neighboring or distant cells delivering their content in form of biologically active molecules (e.g.,
proteins, mRNAs, miRNAs, and lncRNAs), thus modifying the phenotype of target cells [22,23].
Indeed, there are increasing evidences that tumor cells release exosomes to create an environment
supporting angiogenesis, invasion, tumor proliferation, and the premetastatic niche [24–26]. Moreover,
it has also been shown that tumor-associated fibroblasts, through the release of exosomes, could induce
in breast tumor cells the acquisition of a metastatic phenotype [27].
In glioblastoma, exosomes released by tumor cells, containing mRNA, miRNA, and angiogenic
proteins, are able to act on endothelial cells, favoring the development of a tumor-permissive
microenvironment [28]. Exosome miRNAs were associated with gliomagenesis by modulation of
several signaling pathways [29–31]. miRNAs are non-coding single stranded RNAs of 18–27 nucleotides
that influence various cellular processes decreasing the level of translation of their target mRNAs [32].
The packaging of miRNAs and proteins inside the exosomes is a selective process, as their content
can be modulated at different stages of cancer development, mirroring the physiological state of the
cell of origin, thus representing prognostic/predictive biomarkers [33–35].
Altogether, this knowledge contributes to increased attention on the TME as a novel source of
therapeutic targets and markers of disease progression [36,37].
Cells residing in the TME would be less prone to develop drug-resistance, being devoid of
mutations unlike cancer cells. Indeed, multiple TME-directed therapies are now under evaluation in
clinical trials [38–40].
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To deepen the comprehension of the role played by the TME on the malignant progression of LGG,
we have taken advantage of our previously established in vitro model of glioma microenvironment,
represented by glioma-associated stem cells and their released exosomes [41].
Glioma-associated stem cells (GASC), isolated both from human low- and high-grade glioma samples,
are characterized by an undifferentiated mesenchymal phenotype, clonogenicity, and multipotency [41–44].
This cell population does not show genetic aberrations of the tumor of origin, and it is devoid of
tumor-initiating properties, in vivo; nevertheless, GASC are characterized by the ability to grow in
an anchorage-independent way, in vitro. Moreover, GASC from LGG were endowed with prognostic
potential when comparing low-grade and high-grade gliomas’ specific surface markers. We also
demonstrated that GASC could prognostically stratify LGG based on the expression of the NF-κB-related
transcriptional program exerting their tumor-supporting properties through the stimulation of cytokines
such as TNFα, IL1β, and IL-6, constituting new targets for novel adjuvant therapies.
In our in vitro model, GASC, from both HGG and LGG, were able to increase the in vitro
aggressiveness of glioblastoma, through the release of exosomes, although those from LGG at a
significant lower extent [41]. These data suggest that the degree of the tumor-supporting ability was
proportional to the grade of malignancy of the tumor of origin. We have also identified a pro-migratory
protein (SEMA-7A) able to promote the motility of glioma stem cells (GSC) in vitro, exposed on the
surface of HGG-GASC exosomes [44].
As we have already demonstrated the prognostic value of GASC and assessed the importance of
exosomes in sustaining the bidirectional crosstalk with tumor cells through the release of bioactive
molecules, in this paper, we aimed at dissecting the miRNA content of exosomes derived from either
GASC isolated from LGG characterized by a good prognosis or GASC isolated from LGG characterized
by a rapid anaplastic transformation, regardless of WHO classification status. Taking advantage of
deep sequencing and bioinformatic tools, we identified putative miRNAs possibly responsible for the
heterogeneity in prognosis that characterizes LGG.
2. Experimental Section
The project had approval of the local ethics committee (Consents 102/2011/Sperand 196/2014/Em),
and all experiments were conducted after written informed consent from all the patients enrolled
according to the Declaration of Helsinki.
2.1. GASC Cell Culture, Supernatant Collection, and Exosomes Isolation
Human glioma samples derived from patients who underwent anaplastic transformation either
within 48 months (LGG_BAD; n = 3) or ≥7 years (LGG_GOOD; n = 3) after surgery were collected at the
Department of Neurosurgery, Santa Maria della Misericordia, University Hospital in Udine. GASC cells
were isolated and cultured as in [41]. Briefly, glioma tissues were mechanically and enzymatically
dissociated followed by a biophysical selection of cells smaller than 40 µm in diameter. Cells were
expanded in vitro for three passages in selective expansion medium. For supernatant collection,
cells were seeded at 6000 cells/cm2 in 100 mm Petri dishes in a 5% CO2 and 5% O2 incubator and
maintained until 70–80% confluence (approximately 48 h) in exosome-depleted expansion medium.
Exosomes were isolated from the collected GASC supernatants using ExoQuick-TC Exosome
precipitation solution (System Biosciences, Palo Alto, CA, USA), according to manufacturer’s
instructions. Briefly, supernatants were collected after conditioning and centrifuged at 3000 g for
30 min at 4 ◦C to remove cells and debris; samples were then filtered through a 0.2 µm filter with a
syringe to remove particles larger than 200 nm in diameter. Finally, supernatants were concentrated
using centrifugal filter units (Amicon-Ultra15, Merck Millipore, Burlington, MA, USA) in regenerated
cellulose membranes, with a pore size of 100 kDa, by centrifugation at 4700 g for 20 min at 4 ◦C.
The ultra-filtered supernatants were then incubated with ExoQuick-TC Exosome precipitation solution
(System Biosciences, Palo Alto, CA, USA) in a 5:1 dilution overnight at 4 ◦C and centrifuged at 1500 g
for 15 minutes at 4 ◦C. The exosome pellets were resuspended in phosphate-buffered saline (PBS),
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milliQ water or radio immunoprecipitation assay (RIPA) buffer (NaCl 150 mM, 25 mM Tris-HCl, pH 7.6,
1% IGEPAL, (Octylphenoxypoly(ethyleneoxy)ethanol), 0.1% SDS, 1% SodiumDeoxycholate, 1 mM
dithiothreitol, 1 mM Na2 VO4, 1 mM Sodium Fluoride, 0.5 mM Phenylmethanesulfonyl fluoride,
Protease Inhibitor Cocktail, all from Sigma-Aldrich, Milan, Italy)for further analysis.
2.2. Nanoparticle Tracking Analysis
Size and particles’ concentration of exosome preparations were assessed using Nanosight (LM10,
Malvern System Ltd., London, UK), equipped with a 405 nm laser. Analyses were performed as in [44].
Briefly, after optimizing camera level (15) and detection threshold (6), 1:1000 diluted exosome-enriched
fractions were recorded for 60 s and analyzed by Nanoparticle Tracking Analysis (NTA) software
(LM10, Malvern System Ltd., UK).
2.3. MACSPlex Analysis
Multiplex surface marker analysis was performed using MACSPlex Exosome, human, Kit (Miltenyi
Biotec, Bergisch-Gladbach, Germany) according to manufacturers’ protocol. The short protocol for
1.5 mL reagent tubes was performed, using a combination of Allophycocyanin (APC)-stained CD9-,
CD63-, and CD81-detection antibodies, which, in combination with a detection reagent, allows
qualitative and semiquantitative analysis of 37 exosome surface epitopes. The analysis was performed
in triplicate comparing the samples with the relative buffer (PBS) and the kit buffer, standardizing
analysis for particles’ concentration (5 × 109 particles). Flow cytometric analysis was performed on
FASCanto (BD Biosciences, San Jose, CA, USA, http://www.bdbiosciences.com) and analyzed with
the FACSDiva software (BD Biosciences, San Jose, CA, USA). For analysis, the median APC intensity
(MFI) of all the 37 captured markers was normalized for PBS, buffer control, and isotypic control,
and negative values were excluded.
2.4. Western Blot
Exosomes and cells proteins were obtained by lysis in RIPA buffer. Thirty micrograms of proteins
were resolved on SDS-PAGE (Gel Tris-Glycine 10%), transferred, and immobilized on a 0.45 µm
nitrocellulose membrane (Amersham, London, UK). Membranes were blocked by incubation for one
hour at RT with 5% bovine serum albumin in Tris-Buffered Saline (TBS) (Tris-HCl 50mM, pH 7.4,
NaCl 150 mM, all from Sigma-Aldrich, Italy) containing 0.2% Tween 20 (Sigma-Aldrich, Milan,
Italy) and hybridized overnight at 4 ◦C with mouse monoclonal to Tumor Susceptibility Gene 101
protein (TSG101) (1:500 dilution) (Abcam, Cambridge, UK), rabbit monoclonal to calnexin (1:1000
dilution) (Cell Signaling Technology, Danvers, MA, USA).Primary antibodies were detected using
horseradish peroxidase-linked secondary antibodies (anti-mouse 1:1000 dilution; anti-rabbit 1:5000
dilution) (DAKO, Cambridge, UK) and visualized using the enhanced chemiluminescent detection
system (SuperSignal West Dura Extended Duration Substrate, Thermo Scientific, Walthman, MA, USA).
2.5. miRNA Extraction, Library Preparation, and Sequencing
miRNA from GASC and their respective exosomes, normalized for the amount of producing cells
and NTA particle number, were extracted using mirVana PARIS kit (Thermo Fisher, Walthman, MA,
USA) following manufacturer’s instructions.
A total amount of 2 µg was analyzed using the “TruSeqSmallRNA Sample Prep kit” (Illumina,
San Diego, CA, USA) for library preparation following the manufacturer’s instructions. Both RNA
samples and final libraries were quantified by using the Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA,
USA) and quality tested by Agilent 2100 Bioanalyzer RNA Nano assay (Agilent technologies, Santa Clara,
CA, USA). Libraries were then processed with Illumina cBot for cluster generation on the flowcell,
following the manufacturer’s instructions, and sequenced on single-end 50 bp mode on HiSeq2500
(Illumina, San Diego, CA, USA), averaging 12 million sequenced reads per sample. The CASAVA
1.8.2 version of the Illumina pipeline was used to process raw data for both format conversion and
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de-multiplexing. Upon adapter removal with Cutadapt [45], fragments were mapped to the miRbase [46]
release 20 and human genome hg19 databases. Cufflinks [47], Cuffdiff [48], and the edgeR R/Bioconductor
package [49] were used to evaluate gene expression and pairwise differential expression, respectively.
2.6. miRNA Targets Functional Enrichment Analysis
We retrieved differentially expressed miRNA (DE-miRNA) human validated targets through the
DIANA-mirPath v.3 web-server [50]. Functional enrichment analysis was performed querying the
Kyoto Encyclopedia of Genes and Genomes (KEGG) database (p ≤ 0.05), applying the “pathways
union” method and retaining the top15 most significantly enriched terms. DIANA-miRPath v3.0
extends the Fisher’s exact test, EASE score, and false discovery rate methodologies, with the use of
unbiased empirical distributions.
2.7. Survival Analysis
miRNA expression data (HiSeq, miRgene level; RPM, Log2(Val+1); no distinction could be made
between the -5p and -3p forms) and clinical data were downloaded from the LinkedOmics portal for
TCGA-LGG lower grade glioma patients (n = 512 and n = 515, respectively; http://linkedomics.org/
data_download/TCGA-LGG/). We removed patients that lacked either expression (n = 1) or overall
survival data (n = 34), defining the final cohort (n = 477) that was used for the following studies.
The prognostic value of the four examined DE-miRNA signatures was evaluated using the RTCGA,
clinical and survival R packages. We stratified patients into “high-expression” and “low-expression”
based on p-value optimization using the “surv_cutpoint” function (minprop = 0.33). The difference
in overall survival rates between the two subgroups was verified applying a log-rank test (p-value
< 0.05), and Kaplan–Meier plots were finally drawn to summarize the data. We finally performed a
multivariate Cox regression analysis to evaluate the prognostic significance of DE-miRNA signatures
with respect to clinical covariates (sex, age, and histological subtype).
3. Results
3.1. Characterization of Exosomes Derived from LGG with Different Prognosis
GASC cells were isolated from n = 3 LGG patients who underwent anaplastic transformation
within 48 months (GASC_BAD) and n = 3 LGG patients who underwent anaplastic transformation
after 7 years (GASC_GOOD). Exosomes, defined as EXO_BAD and EXO_GOOD, depending on the
GASC of origin, were precipitated from GASC supernatants through polymer-based precipitation
and further characterized. Figure 1a shows a representative nanoparticle tracking analysis of an
examined sample. Size data support the exosome nature of the particles, being within a range of 50 and
150 nm. Overall, EXO_GOOD and EXO_BAD did not significantly differ in terms of size (91 ± 10 nm
vs. 95 ± 10 nm; p-value: 0.35) and concentration (1.9 ± 0.3 × 1012 particles/mL vs. 1.6 ± 0.2 × 1012
particles/mL; p-value: 0.52).
To characterize GASC-derived exosomes, we performed MACSPLEX analysis and Western
blot. Figure 1b,c show the surface immunophenotype of EXO_BAD and EXO_GOOD. As reported,
all nanoparticle preparations expressed, consistently with exosome standards, the tetraspanins CD9, CD81,
and CD63. Moreover, all GASC exosomes expressed high levels of the surface markers CD105, SSEA4,
CD44, CD29, and CD20 and low levels of CD56, CD25, CD49E, ROR1, HLA-ABC, MCSP, and CD133.
Figure 1d shows Western blots performed on representative exosome preparations for the detection
of the TSG101 protein, a key component of the ESCRT-I complex (endosomal sorting complex required
for transport), commonly used as protein marker for exosomes, and calnexin, marker protein for the
endoplasmic reticulum. As shown, TSG101 is expressed in all exosome preparations, and calnexin,
although detectable in exosomes, is strongly depleted compared to GASC secreting cells.
All data suggest that the particles isolated from GASC supernatant, either GASC_GOOD or
GASC_BAD, presented size and surface phenotype typical of exosomes.
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Figure 1. (a) Representative size distribution of an EXO_GOOD sample. Surface phenotype of (b)
EXO_BAD and (c) EXO_GOOD exosomes: histograms represent, as mean ± standard deviation,
the Log median Allophycocyanin (APC) intensity of 15 ma kers. (d) Represen tive Western blot for
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3.2. EXO_GOOD and EXO_BAD Display Different miRNA Profiles
RNAs extracted from GASC_GOOD, EXO_GOOD, GASC_BAD, and EXO_BAD samples were used
for miRNA profiling by NGS. A total of 2425 mature miRNAs were efficiently obtained and sequenced.
Moreover, we identified n = 493 miRNAs with normalized average expression > 20 counts in the profiled
samples. Table 1 shows the lists of miRNAs either up- or downregulated in exosomes with respect to
their cellular counterparts (i.e., EXO_GOOD vs. GASC_GOOD and EXO_BAD vs. GASC_BAD).
As reported in Table 1 and Figure 2, some miRNAs were upregulated (n = 13) or downregulated (n = 18)
in both EXO_GOOD and EXO_BAD, with respect to their cellular counterparts. This suggests the existence
of a baseline miRNA profile shared by LGG exosomes, independently from disease aggressiveness.
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Table 1. List of upregulated and downregulated miRNAs in EXO_GOOD, with respect to GASC_GOOD,
and EXO_BAD, in comparison with GASC_BAD. miRNAs reported in bold are specific for each subset,
while the others are similarly expressed in both EXO_GOOD and EXO_BAD.
















































Considering miRNAs distinctively regulated in EXO_GOOD and EXO_BAD, we observed, in the
first group, two miRNAs upregulated, and 19 miRNAs downregulated, while, in the second one,
12 miRNAs upregulated and 15 downregulated.
All lists of miRNAs with logFC, p-value, and FDR are displayed in Supplementary Table S1.
3.3. Most of Modulated miRNAs in EXO_GOOD and EXO_BAD Are Endowed with Prognostic Significance
Before further investigating the differentially expressed miRNAs, we decided to evaluate the
ability of these miRNA signatures to predict overall survival (OS) in 477 newly diagnosed diffuse LGG
patients comprised within The Cancer Genome Atlas (TCGA) database.
All miRNA signatures identified significantly predicted prognosis, as shown in Figure 3. Moreover,
univariate analysis showed the same trend for all the signatures tested, indicating that almost all
miRNAs found in LGG GASC exosomes, either with good or bad prognosis, once expressed at high
levels, correlated with a poorer overall survival. These data are very interesting, as we were expecting
to find an opposite trend for upregulated or downregulated signatures, being the first ones associated
with a bad prognosis and the second ones with a good prognosis. The fact that both signatures are,
instead, endowed with a poor prognosis suggests that the tumor-supporting function of exosomes is
mainly mediated by the transfer of oncogenic miRNAs rather than by the reduced transfer of tumor
suppressive miRNAs. miRNAs downregulated in exosomes are possibly the expression of oncogenic
miRNAs, which act mainly at the intracellular level.
To further validate the prognostic value of these signatures, we performed a multivariate analysis,
displayed in Figure 4, including other parameters such as histological subtype, age, and sex. As shown,
even though the last parameter did not correlate with prognosis, age and histological subtype were
significantly capable to predict prognosis, along with the exosome miRNA signatures.
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Biomedicines 2020, 8, 564 9 of 22
All data reported suggest that exosomes derived from the TME of LGG have a miRNA content
endowed with a significant prognostic value.
3.4. Functional Enrichment Analysis Reveals Common Pathways in EXO_GOOD and EXO_BAD
As all miRNA subsets, once expressed at high levels, predicted a poorer OS, we decided to further
investigate the possible mechanisms responsible for the worse prognosis of some LGG. For this reason,
we proceeded with the functional annotation of the miRNA subsets upregulated and downregulated
in EXO_GOOD and EXO_BAD. Tables 2 and 3 list the 15 most statistically significant KEGG pathways
affected by the dysregulated miRNAs in EXO_GOOD_UP, EXO_GOOD_DOWN, EXO_BAD_UP,
and EXO_BAD_DOWN subsets along with the number of target genes and miRNAs involved, in each
subset, in the different KEGG pathways. Supplementary Table S2 reports all the results obtained using
DIANA-mirPATH with all the lists of miRNAs, the list of targets for each miRNA, and the complete
KEGG pathway annotation.
Table 2. Top 15 significant Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways associated with
the specific lists of miRNAs dysregulated in EXO_GOOD_UP and EXO_GOOD_DOWN, respectively.
Table reports the p-value, number of genes, and miRNAs involved in the annotated KEGG pathways.
EXO_GOOD_UP EXO_GOOD_DOWN
KEGG Pathway p-Value #Genes #miRNAs KEGG Pathway p-Value #Genes #miRNAs
Proteoglycans in
cancer 1.50 × 10
−9 56 3 Prion diseases 0 11 4
Viral carcinogenesis 8.92 × 10−9 59 6
Fatty acid
biosynthesis 0 5 8
Glioma 2.52 × 10−6 30 6 Steroid biosynthesis 0 9 9
Chronic myeloid
leukemia 5.74 × 10
−6 34 4 Fatty acidmetabolism 0 19 9
MicroRNAs in
cancer 1.56 × 10
−4 26 4 Viral carcinogenesis 0 119 11
Non-small cell lung
cancer 3.37 × 10
−4 21 2 Hippo signalingpathway 0 91 15
Renal cell
carcinoma 4.01 × 10
−3 23 3 ECM-receptorinteraction 0 39 17
Prostate cancer 4.31 × 10−3 33 3
Proteoglycans in
cancer 0 132 17








5.85 × 10−3 9 2 Lysine degradation 2.89 × 10−15 26 11
Pancreatic cancer 7.21 × 10−3 27 3 Pathways in cancer 1.69 × 10−13 197 12
Lysine degradation 9.84 × 10−3 12 3 Hepatitis B 8.91 × 10−12 77 9
TGF-beta signaling
pathway 1.04 × 10
−2 25 3 Glioma 1.70 × 10−10 43 14
FoxO signaling
pathway 1.10 × 10
−2 38 2 TGF-beta signalingpathway 1.13 × 10
−9 56 12
As expected, upregulated and downregulated miRNAs acted on different KEGG pathways,
while there was a strong similarity between KEGG pathways modulated by EXO_GOOD and EXO_BAD
(Tables 2 and 3). In fact, downregulated miRNAs, independently from the origin, EXO_GOOD or
EXO_BAD, were mainly acting on cell metabolism, cell growth, and cell–cell matrix interaction.
Upregulated miRNAs were instead modulating KEGG pathways associated with different cancers.
In order to understand how EXO_BAD could be responsible for a more aggressive phenotype,
we focused our attention on two KEGG pathways, i.e., “Glioma” and “Proteoglycans in cancer”,
modulated by both up- and downregulated exosomes, either in EXO_BAD or EXO_GOOD.
Biomedicines 2020, 8, 564 10 of 22
Table 3. Top 15 significant KEGG pathways associated with the specific lists of miRNAs dysregulated
in EXO_BAD_UP and EXO_BAD_DOWN, respectively. Table reports the p-value, number of genes,
and miRNAs involved in the annotated KEGG pathways.
EXO_BAD_UP EXO_BAD_DOWN
KEGG Pathway p-Value #Genes #miRNAs KEGG Pathway p-Value #Genes #miRNAs
Fatty acid
biosynthesis 0 3 3 Prion diseases 0 7 2
Viral carcinogenesis 2.22 × 10−16 87 9
Fatty acid
biosynthesis 0 4 8
Proteoglycans in
cancer 2.72 × 10
−11 80 6 Fatty acidmetabolism 0 22 9
Prion diseases 1.08 × 10−10 1 1 Viral carcinogenesis 0 121 10
Chronic myeloid
leukemia 1.00 × 10
−8 48 7 Hippo signalingpathway 0 83 14
Glioma 6.75 × 10−6 33 7
Proteoglycans in
cancer 0 137 14
Adherens junction 1.59 × 10−5 29 5
ECM-receptor
interaction 0 43 19
Non-small cell lung
cancer 3.00 × 10
−5 31 5 Steroid biosynthesis 1.11 × 10−16 6 9
Prostate cancer 2.55 × 10−4 45 5 Adherens junction 7.77 × 10−16 57 12
Pancreatic cancer 4.83 × 10−4 38 5 Lysine degradation 2.00 × 10−15 23 9
Renal cell
carcinoma 2.50 × 10





2.70 × 10−3 11 3 Glioma 2.96 × 10−11 47 10
Hepatitis B 3.16 × 10−3 47 4 Cell cycle 1.02 × 10−10 85 6
Pathways in cancer 3.39 × 10−3 125 4 Hepatitis B 9.02 × 10−10 90 8
Endometrial cancer 8.10 × 10−3 21 4 Pathways in cancer 9.96 × 10−9 225 9
3.5. Specific miRNAs of EXO_BAD Could Provide Insight into the Poorer Outcome of Some LGG
Since we were interested in understanding how the miRNA content of EXO_BAD could
be responsible for the more aggressive phenotype of LGG_BAD, we focused our attention on
EXO_BAD miRNAs.
Considering the lists of miRNAs that in EXO_BAD were included in “Glioma” and “Proteoglycans
in cancer” KEGG pathways (Supplementary Table S3), we noticed that, while some miRNAs were
similarly regulated in EXO_GOOD (i.e., upregulated or downregulated in both EXO_GOOD and
EXO_BAD), others were selectively modulated only in EXO_BAD. We hypothesized that the first
group of miRNAs could represent a shared signature of LGG exosomes, independent from tumor
aggressiveness, while the second one an exosome signature specific for LGG with a bad prognosis.
Therefore, among the EXO_BAD miRNAs involved in the KEGG pathways of “Glioma” (Table 4)
and “Proteoglycans in cancer” (Table 5), we distinguished miRNAs dysregulated also in EXO_GOOD
(i.e., EXO-SHARED miRNAs) and miRNAs selectively modulated in EXO_BAD (i.e., BAD-SPECIFIC
miRNAs). All the target genes associated with each up- or downregulated miRNA subsets are reported
in Supplementary Table S4.
Then, considering the KEGG pathways “Glioma” (Figure 5a) and “Proteoglycans in cancer”
(Figure 5b), we evaluated how many miRNAs of each group (BAD-SPECIFIC and shared with GOOD)
were involved, how many genes of the pathways could be modulated by upregulated or downregulated
miRNAs, and the significance of the association.
Focusing on the “Glioma” KEGG pathway, we comprehensively recognized, in EXO_BAD,
seven upregulated miRNAs modulating 33 predicted genes and 10 downregulated miRNAs modulating
47 genes (Table 3). Interestingly, the two BAD-SPECIFIC upregulated miRNAs and the three
BAD-SPECIFIC downregulated miRNAs were able to modulate, respectively, 65 (21/33) and 85% (40/47)
of the predicted target genes (Figure 5a). Similarly, the three BAD-SPECIFIC upregulated and the five
BAD-SPECIFIC downregulated miRNAs in EXO_BAD were able to modulate 57.5 and 80.3% of the
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predicted genes included in the “Proteoglycans in cancer” KEGG pathway, respectively (Table 3 and
Figure 5b). As a whole, this suggests that, in spite of their low number, BAD-SPECIFIC miRNAs could
regulate most of the predicted target genes included in the two considered KEGG pathways.
Table 4. List of downregulated and upregulated miRNAs in EXO_BAD involved in the KEGG pathway
of “Glioma”, distinguishing miRNAs selectively modulated in EXO_BAD (BAD-SPECIFIC) from those




EXO-SHARED: hsa-miR-122-5p, hsa-miR-1246, hsa-miR-126-5p,
hsa-miR-142-5p, hsa-miR-378d
DOWNREGULATED
BAD-SPECIFIC: hsa-miR-29b-3p, hsa-miR-34a-5p, hsa-miR-497-5p
EXO-SHARED: hsa-let-7a-5p, hsa-let-7e-5p, hsa-let-7f-5p, hsa-miR-193a-3p,
hsa-miR-29a-3p, hsa-miR-34c-5p, hsa-miR-454-3p
Table 5. List of downregulated and upregulated miRNAs in EXO_BAD involved in the KEGG
pathway of “Proteoglycans in cancer”, distinguishing miRNA selectively modulated only in EXO_BAD
(BAD-SPECIFIC) from those similarly modulated in EXO_GOOD (EXO-SHARED).
PROTEOGLYCANS IN CANCER
UPREGULATED BAD-SPECIFIC: hsa-miR-126-3p, hsa-miR-182-5p, hsa-miR-223-3pEXO-SHARED: hsa-miR-122-5p, hsa-miR-126-5p, hsa-miR-142-3p
DOWNREGULATED
BAD-SPECIFIC: hsa-miR-29b-3p, hsa-miR-29c-3p, hsa-miR-34a-5p,
hsa-miR-497-5p, hsa-miR-582-3p
EXO-SHARED: hsa-let-7a-5p, hsa-let-7e-5p, hsa-let-7f-5p, hsa-miR-140-5p,
hsa-miR-193a-3p, hsa-miR-21-3p, hsa-miR-29a-3p, hsa-miR-374a-3p,
hsa-miR-454-3p
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Figure 5. Histograms displaying the p-value, number of genes, and number of miRNAs involved in the
KEGG pathways (a) “Glioma” and (b) “Proteoglycans in cancer”, distinguishing upregulated (UP) and
downregulated (DOWN) as well as BAD-SPECIFIC (EXO_BAD) and EXO-SHARED (EXO) miRNAs.
We further explored the genes, included in the “Glioma” (Figure 6 and Table 6) and “Proteoglycans
in cancer” (Figure 7 and Table 7) KEGG pathways, regulated by miRNAs either BAD-SPECIFIC
or EXO-SHARED.
In fact, considering the 33 genes of the “Glioma” pathway modulated by upregulated miRNAs,
six were exclusively targeted by BAD-SPECIFIC miRNAs, while the remaining were targets of either
EXO-SHARED (n = 12) or both EXO-SHARED and BAD-SPECIFIC (n = 15) miRNAs (Figure 6). Similarly,
15 out of 47 target genes of downregulated miRNAs were modulated by BAD-SPECIFIC miRNAs. Table 6
lists the validated genes targeted by BAD-SPECIFIC miRNAs, EXO-SHARED miRNAs, or both.
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AKT2, BRAF, CALM1, CALM2, CALM3, CCND1, CDK4, 
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Concerning the “Proteoglycans in cancer” KEGG pathway, as reported in Figure 7 and Table 7, 
among the 80 modulated genes of upregulated miRNAs, 24 were exclusively targeted by BAD-
SPECIFIC miRNAs, while the remaining were targets of either EXO-SHARED (n = 34) or both EXO-
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upregulated “BAD-SPECIFIC” (green), “EXO-SHARED” (blue), or by both gr ups of miRNAs (greenish
blue). (b) Number of validated target genes modulated exclusively by downregulated “BAD-SPECIFIC”
(yellow), “EXO-SHARED” (red), or by both groups of miRNAs (orange). Genes belonging to each
group are listed in Table 6.
Table 6. “Glioma” KEGG pathway: list of validated target genes modulated only by “BAD-SPECIFIC”,
“EXO-SHARED”, or by both “BAD-SPECIFIC” and “EXO-SHARED” miRNAs (COMMON TARGETS).
miRNAs VALIDATED TARGETS
UPREGULATED
“BAD-SPECIFIC” only AKT3, C KN1A, N AS, PIK3R1, RB1, SHC1
COMMON TARGETS AKT1, CALM1, CCND1, CDK4, CDK6, E2F1, E2F3, IGF1R,MAPK1, PIK3CA, PIK3CB, PIK3CD, PIK3R2, SOS1, TP53
“EXO- ” only CALM2, E F2, EGFR, GRB2, KRAS, D 2, MTOR,PIK3CG, PLCG1, PTEN, RAF1, SOS2
DOWNREGULATED
“BAD-SPECIFIC” only AKT1, AKT3, ARAF, CDKN2A, E2F2, GRB2, IGF1, MAP2K1,MAP2K2, MTOR, PIK3CA, PRKCB, RAF1, SOS2, TGFA
COMMON TARGETS
AKT2, BRAF, CALM1, CALM2, CALM3, CCND1, CDK4,
CDK6, CDKN1A, E2F1, E2F3, EGFR, IGF1R, MAPK1,
MDM2, NRAS, PDGFRA, PDGFRB, PIK3R1, PIK3R2,
PIK3R3, PLCG1, PTEN, SOS1, TP53
“EXO-SHARED” only CAMK2D, KRAS, PDGFA, PDGFB, PIK3CB, PRKCA, RB1
Concerning the “Proteoglycans in cancer” KEGG pathway, as reported in Figur 7 and Table 7,
among the 80 modulated genes of upregulated miRNAs, 24 were exclusively targeted by BAD-SPECIFIC
miRNAs, while the remaining were targets of either EXO-SHARED (n = 34) or both EXO-SHARED
and BAD-SPECIFIC (n = 22) miRNAs. Similarly, among the 137 genes targeted by downregulated
miRNAs, 34 were modulated only by BAD-SPECIFIC miRNAs, while the remaining were targets of
either EXO-SHARED (n = 27) or both EXO-SHARED and BAD-SPECIFIC (n = 76) miRNAs.
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Table 7. “Proteoglycans in cancer” KEGG pathway: list of validated target genes modulated only





AKT3, CDC42, CDKN1A, EIF4B, ELK1, ESR1, FGF2, FZD6,
HIF1A, ITPR3, MET, MMP2, MMP9, MSN, NRAS, PIK3CB,
PIK3R1, PPP1R1, PRKACB, RPS6KB2, SDC4, SOS1,
STAT3, THBS1
COMMON TARGETS
AKT1, CBL, CCND1, CTNNB1, CTTN, FRS2, FZD3, IGF1R,
IQGAP1, ITGB1, MAPK1, MTOR, PDPK1, PIK3CA, PIK3CD,
PIK3R2, RAC1, RDX, ROCK2, SDC2, TP53, VEGFA
“EXO-SHARED” only
ACTB, AKT2, ANK1, ARHGEF12, CD44, DCN, EGFR, FGFR1,
FLNB, FZD1, FZD4, FZD7, GAB1, GRB2, HCLS1, ITGAV, KRAS,
MAPK13, MDM2, MYC, PAK1, PIK3CG, PIK3R5, PLCG1,




AKT1, AKT2, ANK3, ARAF, CBLC, CD44, CD63, COL21A1,
CTTN, ELK1, FGF2, FZD1, GAB1, GPC1, GRB2, HGF, HPSE,
IGF1, ITGA5, ITPR1, MAP2K1, MAP2K2, MAPK12, MMP9,
PIK3CA, PPP1R12B, PRKACA, PRKACB, PRKCB, PRKX,
PTCH1, RAF1, ROCK2, TFAP4
COMMON TARGETS
ACTB, ACTG1, AKT3, ARHGEF12, BRAF, CAV1, CAV2,
CCND1, CDC42, CDKN1A, CTNNB1, DDX5, EGFR, EZR,
FGFR1, FLNB, FN1, FRS2, FZD5, FZD6, GPC3, HIF1A, HSPG2,
IGF1R, IGF2, IQGAP1, ITGAV, ITGB1, ITGB5, ITPR3, MAPK1,
MAPK13, MDM2, MET, MMP2, MSN, MTOR, MYC, NRAS,
NUDT16L1, PDCD4, PIK3R1, PIK3R2, PIK3R3, PLAU, PLAUR,
PLCG1, PPP1CA, PPP1CB, PPP1CC, PPP1R12A, PPP1R12C,
PRKCA, PTPN11, PXN, RDX, RPS6, RRAS, SDC1, SDC2, SDC4,
SLC9A1, SMAD2, SMO, SOS1, SOS2, SRC, STAT3, TGFB1,
TGFB2, THBS1, TP53, VAV2, VEGFA, WNT5A, WNT9A
“EXO-SHARED” only
ARHGEF1, CAMK2D, CASP3, CBL, DROSHA, EIF4B, ESR1,
FAS, FLNA, FLNC, FZD2, FZD3, FZD4, HOXD10, ITGA2,
ITPR2, KDR, KRAS, PIK3CB, PTK2, PTPN6, RAC1, RPS6KB2,
TLR4, VMP1, WNT3A, WNT5B
Altogether, data suggest that, EXO_BAD and EXO_GOOD can generally act on the same KEGG
targets but also specifically on additional elements of the considered pathway.
4. Discussion
WHO grade II gliomas, here defined as LGG, represent a group of usually slow-growing primary
malignant brain tumors, which, however, in 70% of cases undergo recurrence and/or transformation
into tumors with greater malignancy [4]. Thus, LGG outcome is heterogeneous, with an overall
survival ranging from 2 to over 12 years. Predicting the outcome and distinguishing low-risk and
high-risk patients is fundamental to assist clinicians in the decision-making process aimed at not
either overtreating or undertreating patients [3,4,9]. Although age (>40 years), incomplete extent of
resection, radiological progression, and/or neurological symptoms contribute to recognizing high-risk
patients, a better prognostic stratification is required [3,4,9]. The molecular classification of LGG into
three classes (IDH wildtype, IDH mutant only, and IDH mutant and 1p/19q co-deleted), according
to WHO criteria [1], has further contributed to recognize patients at risk of quick progression [5–7].
Beside prognostic stratification, the choice of adjuvant treatments also remains challenging. Available
therapies, radiotherapy and chemotherapy, are burdened by important side effects (e.g., late cognitive
defects after radiotherapy), which limit their use in patients with a long life expectancy.
For this reason, there is an increasing interest of the scientific community in the TME [12,13,39,43].
The TME consists of various types of non-tumor cells, such as endothelial cells, stromal cells, pericytes,
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immune cells, and components of the extracellular matrix. The bidirectional crosstalk between tumor
cells and TME contributes to tumor development and progression by promoting tumor cell proliferation,
invasion, and angiogenesis; reprogramming of energy metabolism, and suppressing cell death and
immune response, well-known hallmarks of cancer [12,13,39,43]. It has been shown that the TME can
predict prognosis, and it is considered an interesting therapeutic target [51]. It has been suggested that
more than ablation of the TME, it might be useful to interrupt the bidirectional crosstalk with tumor
cells or to reverse its phenotype by re-establishing a microenvironment capable of counteracting tumor
growth [51]. It has been shown that, in the tumor, both cancer cells and tumor-associated stromal
cells promote tumor-induced immune suppression, angiogenesis, and metastasis through the release
of exosomes [18–20,27]. The latter, through their content in biologically active molecules, including
miRNAs, can act as a potent intercellular communication system [18,22,28,52,53].
To better investigate the role of the TME in glioma, we have isolated from low-grade and
high-grade gliomas a population of stem cells, named glioma-associated stem cells (GASC). GASC are
a population of tumor derived stem cells representative of the TME: although devoid of the genetic
alterations of the tumor cells, they are able to support, in vitro, the tumor growth [41]. Additionally,
we demonstrated that GASC derived from LGG can independently predict patient prognosis [41],
and, from the transcriptomic analysis of GASC derived from LGG with different prognosis, it was
possible to identify a prognostic gene signature further validated in 530 newly diagnosed diffuse LGG
patients comprised within The Cancer Genome Atlas (TCGA) database [42]. Importantly, GASC exert
their tumor-supporting function through the release of exosomes [41,44]. Specifically, GASC-derived
exosomes are able to increase proliferation, motility, and anchorage-independent growth of both
commercially available glioblastoma cell lines and patient-derived glioma stem cells (GSC) [41,44].
To obtain insights into the TME-related mechanisms, possibly responsible of the more aggressive
behavior of some LGG, we isolated exosomes from the supernatant of GASC derived from both LGG
patients undergoing a rapid malignant transformation (EXO_BAD) and LGG patients experiencing
malignant transformation after at least 7 years (EXO_GOOD).
EXO_BAD and EXO_GOOD were produced with the same yield from GASC_GOOD and
GASC_BAD and shared similar size, concentration, and markers that ascribed them as exosomes.
However, some differences could be detected in their miRNA content. It is important to notice that,
although ultrafiltration using 100 kDa molecular weight cutoffs could remove some RNPs, we cannot
exclude the presence of ribonucleoprotein particles complexes or high-density lipoproteins. Still,
the samples were isolated in the same conditions resulting in a shared medium-derived contaminant
background throughout the experiment.
By taking advantage of deep sequencing technologies, we analyzed the miRNA profiles of both
exosomes and their producing cells. With respect to their cellular counterpart, exosomes were either
enriched in some miRNAs or depleted in others. This is consistent with what previously published:
as shown for mRNA [28,54–56], miRNAs also seem not to be randomly selected and loaded into
exosomes [57–59].
Comparing the miRNAs enriched or depleted in EXO_GOOD and EXO_BAD, with respect to
their cellular counterparts, we identified: 1. a large group of miRNAs similarly regulated in the two
groups and 2. miRNAs differently regulated in EXO_GOOD and EXO_BAD.
Focusing our attention on the miRNA signature shared by GASC exosomes, independently from
patient prognosis, we observed either upregulation or down regulation of both oncosuppressive
and oncogenic miRNAs. For example, with respect to their cellular counterpart, GASC exosomes
resulted in the depletion of many members of the let-7 family. This latter exerts a tumor suppressive
function by inhibiting proliferation and malignancy of glioblastoma cells by targeting both NRAS
and KRAS [60,61] and by modulating microglia activation through TLR7 [62]. On the other hand,
GASC exosomes resulted in the depletion of miR-21 and miR-221, two miRNAs whose oncogenic role
in glioblastomas has been widely demonstrated [63–66]. Similarly, GASC exosomes were enriched
in miR-451 and miR-150, which are known to inhibit GSC growth [67] and glioma cell proliferation,
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invasion and apoptosis through the Akt pathway [68] and to suppress glioma cell proliferation and
migration by targeting MMP1, respectively [69]. Conversely, GASC exosomes were enriched in
miR-1246, responsible for glioma immune escape by targeting TERF2IP [70], and in miR-4516, known to
exert a tumor promoting function by regulating the Hippo pathway in glioblastoma [71]. It would be
extremely interesting to compare this upregulated and downregulated “baseline” miRNA signature
with non-transformed glial cells, to assess if this signature could be representative of glial cells.
Looking instead to the two miRNAs specifically enriched in EXO_GOOD, miR-320c has been
shown to exert a tumor suppressive function in glioma, by acting through the modulation of either
RAF1/MAPK pathway or E2F2, a key transcription factor involved in the regulation of the G1/S
phase [72–74]. Li et al. reported that miR-320c could increase radiosensitivity of glioma cell by
inhibiting SIRT1 through FOXM1 modulation [74]. No information is instead available on a possible
role of miR-4532 in glioma. Regarding the miRNAs selectively upregulated in GASC_BAD, an oncogenic
role, in glioma, has been described for miR-223-3p [75], miR-10b-5p [76,77], and miR-182-5p [78,79],
while miR-338-3p [80,81], miR-204-5p [82], and miR-126-3p [83] were described as oncosuppressive.
Instead, few or no information on the role of miR-4492 [84], miR-4508, miR-7704, miR-4488 [85],
and miR-151b on glioma are available.
To better understand these data of non-univocal interpretation, we decided to verify the possible
clinical significance of the identified exosome signatures in 477 newly diagnosed diffuse LGG patients
comprised within the TCGA database [42]. We considered two signatures corresponding to the miRNA
upregulated in EXO_GOOD and in EXO_BAD and two signatures corresponding to the miRNA
downregulated in EXO_GOOD and in EXO_BAD. Interestingly, all four signatures, if upregulated,
had negative prognostic significance. This suggests that miRNA signatures, although composed of
oncogenic and oncosuppressive miRNAs, are globally the representation of a more aggressive tumor
phenotype. Additionally, the fact that both upregulated and downregulated miRNAs were associated
with a poor prognosis suggests that the tumor supportive function of exosomes is likely mediated by the
delivery of over-expressed miRNAs rather than by the reduced transfer of tumor suppressor miRNAs.
In fact, even miRNAs whose expression is reduced in exosomes were oncogenic. We can therefore
hypothesize that they represent a class of oncogenic miRNA mainly retained at intracellular level.
Consistently, when we proceeded with the functional annotation of miRNAs upregulated and
downregulated in EXO_GOOD and EXO_BAD, we noticed that, independently from the GASC of
origin, upregulated and downregulated miRNAs were targeting different KEGG pathways. In fact,
downregulated miRNAs, either in EXO_GOOD or EXO_BAD, were mainly acting on cell metabolism,
cell growth, and cell–cell matrix interaction. This supports the hypothesis that an intracellular
enrichment of these miRNAs could confer a more aggressive tumor phenotype. Upregulated miRNAs
were instead modulating KEGG pathways associated with different cancers, including glioma, chronic
myeloid leukemia, prostate carcinoma, non-small cell carcinoma, renal cell carcinoma, and pancreatic
carcinoma. This suggests that exosomes can transfer miRNAs able to modulate a more general
“tumor-related mechanism” globally shared by different cancers.
As mentioned, when we compared the KEGG pathways modulated by upregulated EXO_BAD and
EXO_GOOD, no major differences were detected. Same observation could be done for downregulated
miRNAs in EXO_GOOD and EXO_BAD.
Therefore, to get insights into the mechanisms by which EXO_BAD could exert a stronger
tumor-supporting function, we focused our attention on two KEGG pathways shared by all the four
exosome-related signatures: “Glioma” and “Proteoglycan in cancer”. The first one was selected because
it strictly related to our tumor setting. The second one because it is known that proteoglycans can
regulate cell signaling and migration, as well as immune response, by interacting with both extracellular
(extracellular ligands, growth factor receptors, and extracellular matrix) and intracellular (enzymes and
structural proteins) elements [86]. Therefore, proteoglycans are key players in intracellular oncogenic
pathways as well as in tumor–TME crosstalk [86]. Additionally, in glioma, it has been demonstrated
that the expression of heparan sulfate proteoglycans is significantly increased in high grade gliomas,
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with respect to LGG [87], and a similar pattern has been demonstrated for the dermatan sulfate
proteoglycan endocan [88] and the cell surface chondroitin sulfate proteoglycan CD44 [89].
Restricting our analysis to EXO_BAD, we assessed that, while some miRNAs were similarly
upregulated or downregulated in EXO_GOOD, few others were specific of EXO_BAD. We named the
first ones EXO-SHARED miRNAs and the latter BAD-SPECIFIC miRNAs. In particular, miR-126-3p and
miR-182-5p were BAD-SPECIFIC miRNAs upregulated in both “Glioma” and “Proteoglycans in cancer”
KEGG pathways, while miR-223-3p was exclusively upregulated in the second one. Concurrently,
three BAD-SPECIFIC miRNAs (miR-29b-3p, miR-34a-5p, and miR-497-5p) were downregulated in
both “Glioma” and “Proteoglycans in cancer” pathways, and one, miR-582-3p, exclusively in the
“Proteoglycans in cancer” pathway.
miR-182-5p is a well-described oncomiR that, in HGG, is known to promote the proliferative
and invasive capacities of tumor cells through the modulation of either STAT3 or NF-κB signaling
pathways [78,79,90]. Interestingly, analyzing the target genes comprised in the KEGG pathways,
miR-182-5p modulates all the validated targets present in the “Glioma” pathway and most of the targets
present in the “Proteoglycans in cancer” pathway. miR-223 is another well-recognized oncogenic
miRNA, which, in glioblastoma, promotes growth and invasion of tumor cells by targeting the tumor
suppressor PAX6, exerting its function by inhibiting the expression of metalloproteases MMP2 and
MMP9 [91]. As mentioned above, the role of miR-126-3p is more controversial, since it has been
recognized as an oncosuppressive miRNA [83]. However, more recently, its role in retinal angiogenesis
has been demonstrated, both in vitro and in vivo, by protecting endothelial cells from apoptosis [92].
Concerning miRNAs downregulated in the EXO_BAD, miR-34a-5p along with miR-497-5p were
the most involved in the modulation of all predicted targets in both “Glioma” and “Proteoglycans
in cancer” pathways. miR-34a is a p53 transcriptional target poorly expressed in HGG compared to
normal brain tissues [93], and it is known to suppress in vitro and in vivo tumor growth by targeting
c-MET and NOTCH, thus directly modulating glioma cell cycle [94]. Moreover, miR34a has been
reported to modulate glioma cells apoptosis by targeting BCL2 [95] and stimulating senescence in
glioma cells by inducing DNA damage [96]. On the other hand, the clinical significance of miR-497 has
not been fully elucidated yet, but studies described a significant decrease in this miRNA in HGG with
respect to LGG and demonstrated its role in suppressing angiogenesis, by targeting VEGFA [97] and
glioma proliferation and epithelial-to-mesenchymal transition, by modulating WNT3A [98]. Moreover,
decreased expression of miR-497 was associated, in glioma, with a worse prognosis [97,98].
Therefore, our study suggests that targets specific for the aggressive phenotype in LGG are
modulated by miR-182-5p, miR-223-3p, miR-34a-5p, and miR-497-5p. It could be extremely interesting
to further investigate these four miRNAs and the role they play in the evolution of LGG.
It is also worth noting that most of the gene targets in the “Glioma” pathway are included in
the “Proteoglycans in cancer” pathway, thus confirming the importance of proteoglycans in glioma
progression [86–89].
Finally, considering the genes targeted by either BAD-SPECIFIC or EXO-SHARED miRNAs for
each KEGG pathway analyzed, three were the main observations. First, BAD-SPECIFIC miRNAs,
even when fewer than the EXO-SHARED ones, were able to modulate most of the target genes included
in the considered KEGG pathway. Second, BAD-SPECIFIC miRNAs and EXO-SHARED miRNA
presented a certain number of common gene targets, suggesting that there was an increased modulation
of these genes in cells capable of internalizing EXO_BAD. Third, BAD-SPECIFIC miRNAs could hit an
additional number of gene targets, compared to EXO-SHARED miRNAs. This leads us to hypothesize
that the greater tumor-supporting function of EXO_BADs could be linked to their increased ability
to modulate target pathways. Several issues remain to be elucidated. The presence of an increased
expression or downregulation of both oncosuppressive and oncogenic miRNAs can be due to the fact
that LGG are a low-grade tumor anyway, and some miRNAs can be the manifestation of a baseline
tumor suppressive signal, which could explain the slower malignant evolution of this neoplasm.
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The confirmation that miR-182-5p, miR-223-5p, miR-34a-5p, and miR-497-5p could be putative
miRNAs involved in the aggressive phenotype of the tumor requires further in vitro and in vivo study.
Additionally, the mechanisms responsible for the selection of the miRNA cargo remain an
interesting field of study; understanding them could get insights into the biology of cancer and the
possibility to hijack this intracellular communication system to deliver tumor-suppressive messages
able to revert the tumor-supporting function of the TME [51,99]
In conclusion, the widely variable LGG prognosis and the lack of specific adjuvant treatment
requires the identification of novel prognostic markers and therapeutic targets. In this regard, our work
suggested that patient-derived GASC, stem cells representative of the tumor microenvironment,
and their released exosomes could give important insights. We have demonstrated that exosomes
released by GASC isolated from LGG characterized by different prognosis possess a miRNA content
that can modulate key pathways in tumor progression and aggressiveness. We could identify miRNA
signatures endowed with clinical significance, being able to predict prognosis in 477 LGG patients.
Additionally, exosomes derived from GASC of patients with a bad prognosis possess a unique repertoire
of BAD-SPECIFIC miRNAs, possibly responsible for the more aggressive function. Further studies are
required to demonstrate whether this information could lead to novel therapies aimed at targeting the
crosstalk between tumor cells and their tumor-supporting microenvironment.
Supplementary Materials: The following are available online at http://www.mdpi.com/2227-9059/8/12/564/s1,
Table S1: miRNA’s expression in GASC exosomes compared to their cellular counterparts; Table S2: Functional
annotation of each miRNA subset (miRNA targets and KEGG pathways); Table S3: miRNA’s subsets involved in
the “Glioma” and “Proteoglycans in cancer” KEGG pathways; Table S4: miRNA’s targets involved in the “Glioma”
and “Proteoglycans in cancer” KEGG pathways.
Author Contributions: Conceptualization and investigation, I.M. and F.C.; data curation, S.R.; formal analysis,
E.D. and S.P.; methodology, D.M.; resources, M.S. and T.I.; visualization, I.M., F.C., E.D., and D.C.; funding
acquisition, D.C., C.D.L., and M.S.; writing—original draft, I.M., F.C., and E.D.; writing—review and editing, I.M.,
F.C., E.D., D.C., and A.P.B. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by Interreg Italia-Austria 2014–2020: “EXOTHERA-Exosomes for regenerative,
immunosuppressive, neuroprotective, and oncosuppressive therapies”; POR FESR 2014–2020, Regione Friuli
Venezia Giulia: “ARES: Against bRain cancEr: finding personalized therapies with in Silico and in vitro strategies”;
Interreg V-A Italia-Slovenia 2014–2020: “TRANS-GLIOMA—Nuove terapie per il glioblastoma tramite una
piattaforma di ricerca transfrontaliera traslazionale”; Regione Friuli Venezia Giulia, legge regionale 17/2004:
“Glioblastoma—Infiltrazione nei gliomi: nuovo target terapeutico”.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.;
Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization Classification of Tumors of
the Central Nervous System: A summary. Acta Neuropathol. 2016, 131, 803–820. [CrossRef]
2. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.;
Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N. Engl. J. Med. 2005, 352, 987–996. [CrossRef]
3. Ruda, R.; Angileri, F.F.; Ius, T.; Silvani, A.; Sarubbo, S.; Solari, A.; Castellano, A.; Falini, A.; Pollo, B.; Del Basso
De Caro, M.; et al. Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas.
An intersociety (SINch/AINO/SIN) document. J. Neurosurg. Sci. 2020, 64, 313–334. [CrossRef]
4. Soffietti, R.; Baumert, B.G.; Bello, L.; von Deimling, A.; Duffau, H.; Frenay, M.; Grisold, W.; Grant, R.; Graus, F.;
Hoang-Xuan, K.; et al. Guidelines on management of low-grade gliomas: Report of an EFNS-EANO Task
Force. Eur. J. Neurol. 2010, 17, 1124–1133. [CrossRef]
5. Brat, D.J.; Aldape, K.; Colman, H.; Holland, E.C.; Louis, D.N.; Jenkins, R.B.; Kleinschmidt-DeMasters, B.K.;
Perry, A.; Reifenberger, G.; Stupp, R.; et al. cIMPACT-NOW update 3: Recommended diagnostic criteria
for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”.
Acta Neuropathol. 2018, 136, 805–810. [CrossRef]
Biomedicines 2020, 8, 564 18 of 22
6. Brat, D.J.; Verhaak, R.G.; Aldape, K.D.; Yung, W.K.; Salama, S.R.; Cooper, L.A.; Rheinbay, E.; Miller, C.R.;
Vitucci, M.; Morozova, O.; et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade
Gliomas. N. Engl. J. Med. 2015, 372, 2481–2498. [CrossRef]
7. Ceccarelli, M.; Barthel, F.P.; Malta, T.M.; Sabedot, T.S.; Salama, S.R.; Murray, B.A.; Morozova, O.; Newton, Y.;
Radenbaugh, A.; Pagnotta, S.M.; et al. Molecular Profiling Reveals Biologically Discrete Subsets and
Pathways of Progression in Diffuse Glioma. Cell 2016, 164, 550–563. [CrossRef]
8. Eckel-Passow, J.E.; Lachance, D.H.; Molinaro, A.M.; Walsh, K.M.; Decker, P.A.; Sicotte, H.; Pekmezci, M.;
Rice, T.; Kosel, M.L.; Smirnov, I.V.; et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations
in Tumors. N. Engl. J. Med. 2015, 372, 2499–2508. [CrossRef]
9. Cesselli, D.; Ius, T.; Isola, M.; Del Ben, F.; Da Col, G.; Bulfoni, M.; Turetta, M.; Pegolo, E.; Marzinotto, S.;
Scott, C.A.; et al. Application of an Artificial Intelligence Algorithm to Prognostically Stratify Grade II
Gliomas. Cancers (Basel) 2019, 12, 50. [CrossRef]
10. Bai, H.; Harmanci, A.S.; Erson-Omay, E.Z.; Li, J.; Coskun, S.; Simon, M.; Krischek, B.; Ozduman, K.; Omay, S.B.;
Sorensen, E.A.; et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression.
Nat. Genet. 2016, 48, 59–66. [CrossRef]
11. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [CrossRef]
12. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [CrossRef]
13. Patel, S.; Ngounou Wetie, A.G.; Darie, C.C.; Clarkson, B.D. Cancer secretomes and their place in supplementing
other hallmarks of cancer. Adv. Exp. Med. Biol. 2014, 806, 409–442. [CrossRef] [PubMed]
14. Pietras, K.; Ostman, A. Hallmarks of cancer: Interactions with the tumor stroma. Exp. Cell Res. 2010, 316,
1324–1331. [CrossRef] [PubMed]
15. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T.L.; Fuller, C.; Hamner, B.; Oh, E.Y.; Gaber, M.W.;
Finklestein, D.; Allen, M.; et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11, 69–82.
[CrossRef]
16. Cheng, L.; Huang, Z.; Zhou, W.; Wu, Q.; Donnola, S.; Liu, J.K.; Fang, X.; Sloan, A.E.; Mao, Y.; Lathia, J.D.;
et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell
2013, 153, 139–152. [CrossRef]
17. Lathia, J.D.; Heddleston, J.M.; Venere, M.; Rich, J.N. Deadly teamwork: Neural cancer stem cells and the
tumor microenvironment. Cell Stem Cell 2011, 8, 482–485. [CrossRef]
18. Azmi, A.S.; Bao, B.; Sarkar, F.H. Exosomes in cancer development, metastasis, and drug resistance:
A comprehensive review. Cancer Metastasis Rev. 2013. [CrossRef]
19. Peinado, H.; Aleckovic, M.; Lavotshkin, S.; Matei, I.; Costa-Silva, B.; Moreno-Bueno, G.; Hergueta- Redondo, M.;
Williams, C.; Garcia-Santos, G.; Ghajar, C.; et al. Melanoma exosomes educate bone marrow progenitor cells
toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18, 883–891. [CrossRef]
20. Taylor, D.D.; Gercel-Taylor, C. Exosomes/microvesicles: Mediators of cancer-associated immunosuppressive
microenvironments. Semin. Immunopathol. 2011, 33, 441–454. [CrossRef]
21. Thery, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.;
Arab, T.; Archer, F.; Atkin-Smith, G.K.; et al. Minimal information for studies of extracellular vesicles 2018
(MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the
MISEV2014 guidelines. J. Extracell. Vesicles 2018, 7, 1535750. [CrossRef]
22. Simons, M.; Raposo, G. Exosomes–vesicular carriers for intercellular communication. Curr. Opin. Cell Biol.
2009, 21, 575–581. [CrossRef]
23. Tkach, M.; Thery, C. Communication by Extracellular Vesicles: Where We Are and Where We Need to Go.
Cell 2016, 164, 1226–1232. [CrossRef]
24. Arita, T.; Ichikawa, D.; Konishi, H.; Komatsu, S.; Shiozaki, A.; Ogino, S.; Fujita, Y.; Hiramoto, H.; Hamada, J.;
Shoda, K.; et al. Tumor exosome-mediated promotion of adhesion to mesothelial cells in gastric cancer cells.
Oncotarget 2016, 7, 56855–56863. [CrossRef]
25. Khalyfa, A.; Almendros, I.; Gileles-Hillel, A.; Akbarpour, M.; Trzepizur, W.; Mokhlesi, B.; Huang, L.;
Andrade, J.; Farre, R.; Gozal, D. Circulating exosomes potentiate tumor malignant properties in a mouse
model of chronic sleep fragmentation. Oncotarget 2016, 7, 54676–54690. [CrossRef]
26. Costa-Silva, B.; Aiello, N.M.; Ocean, A.J.; Singh, S.; Zhang, H.; Thakur, B.K.; Becker, A.; Hoshino, A.;
Mark, M.T.; Molina, H.; et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver.
Nat. Cell Biol. 2015, 17, 816–826. [CrossRef]
Biomedicines 2020, 8, 564 19 of 22
27. Luga, V.; Zhang, L.; Viloria-Petit, A.M.; Ogunjimi, A.A.; Inanlou, M.R.; Chiu, E.; Buchanan, M.; Hosein, A.N.;
Basik, M.; Wrana, J.L. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast
cancer cell migration. Cell 2012, 151, 1542–1556. [CrossRef]
28. Skog, J.; Wurdinger, T.; van Rijn, S.; Meijer, D.H.; Gainche, L.; Sena-Esteves, M.; Curry, W.T., Jr.; Carter, B.S.;
Krichevsky, A.M.; Breakefield, X.O. Glioblastoma microvesicles transport RNA and proteins that promote
tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10, 1470–1476. [CrossRef]
29. Kucharzewska, P.; Christianson, H.C.; Welch, J.E.; Svensson, K.J.; Fredlund, E.; Ringner, M.; Morgelin, M.;
Bourseau-Guilmain, E.; Bengzon, J.; Belting, M. Exosomes reflect the hypoxic status of glioma cells and
mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl. Acad.
Sci. USA 2013, 110, 7312–7317. [CrossRef]
30. Arscott, W.T.; Tandle, A.T.; Zhao, S.; Shabason, J.E.; Gordon, I.K.; Schlaff, C.D.; Zhang, G.; Tofilon, P.J.;
Camphausen, K.A. Ionizing radiation and glioblastoma exosomes: Implications in tumor biology and cell
migration. Transl. Oncol. 2013, 6, 638–648. [CrossRef]
31. Zhang, L.; Zhang, S.; Yao, J.; Lowery, F.J.; Zhang, Q.; Huang, W.C.; Li, P.; Li, M.; Wang, X.; Zhang, C.; et al.
Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature
2015, 527, 100–104. [CrossRef]
32. Mendell, J.T. MicroRNAs: Critical regulators of development, cellular physiology and malignancy. Cell Cycle
2005, 4, 1179–1184. [CrossRef]
33. Valadi, H.; Ekstrom, K.; Bossios, A.; Sjostrand, M.; Lee, J.J.; Lotvall, J.O. Exosome-mediated transfer of
mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9,
654–659. [CrossRef]
34. Fujita, Y.; Yoshioka, Y.; Ochiya, T. Extracellular vesicle transfer of cancer pathogenic components. Cancer Sci.
2016, 107, 385–390. [CrossRef]
35. Mohammadi, S.; Yousefi, F.; Shabaninejad, Z.; Movahedpour, A.; Mahjoubin Tehran, M.; Shafiee, A.;
Moradizarmehri, S.; Hajighadimi, S.; Savardashtaki, A.; Mirzaei, H. Exosomes and cancer: From oncogenic
roles to therapeutic applications. IUBMB Life 2020, 72, 724–748. [CrossRef]
36. Place, A.E.; Jin Huh, S.; Polyak, K. The microenvironment in breast cancer progression: Biology and
implications for treatment. Breast Cancer Res. 2011, 13, 227. [CrossRef]
37. Codrici, E.; Enciu, A.M.; Popescu, I.D.; Mihai, S.; Tanase, C. Glioma Stem Cells and Their Microenvironments:
Providers of Challenging Therapeutic Targets. Stem Cells Int. 2016, 2016, 5728438. [CrossRef]
38. Junttila, M.R.; de Sauvage, F.J. Influence of tumour micro-environment heterogeneity on therapeutic response.
Nature 2013, 501, 346–354. [CrossRef]
39. Quail, D.F.; Bowman, R.L.; Akkari, L.; Quick, M.L.; Schuhmacher, A.J.; Huse, J.T.; Holland, E.C.; Sutton, J.C.;
Joyce, J.A. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.
Science 2016, 352, aad3018. [CrossRef]
40. Schumacher, T.; Bunse, L.; Pusch, S.; Sahm, F.; Wiestler, B.; Quandt, J.; Menn, O.; Osswald, M.; Oezen, I.;
Ott, M.; et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014, 512, 324–327.
[CrossRef]
41. Bourkoula, E.; Mangoni, D.; Ius, T.; Pucer, A.; Isola, M.; Musiello, D.; Marzinotto, S.; Toffoletto, B.;
Sorrentino, M.; Palma, A.; et al. Glioma-associated stem cells: A novel class of tumor-supporting cells able to
predict prognosis of human low-grade gliomas. Stem Cells 2014, 32, 1239–1253. [CrossRef]
42. Ius, T.; Ciani, Y.; Ruaro, M.E.; Isola, M.; Sorrentino, M.; Bulfoni, M.; Candotti, V.; Correcig, C.; Bourkoula, E.;
Manini, I.; et al. An NF-kappaB signature predicts low-grade glioma prognosis: A precision medicine
approach based on patient-derived stem cells. Neuro Oncol. 2018, 20, 776–787. [CrossRef]
43. Manini, I.; Caponnetto, F.; Dalla, E.; Ius, T.; Pepa, G.M.D.; Pegolo, E.; Bartolini, A.; Rocca, G.; Menna, G.;
Loreto, C.D.; et al. Heterogeneity Matters: Different Regions of Glioblastoma Are Characterized by Distinctive
Tumor-Supporting Pathways. Cancers (Basel) 2020, 12, 960. [CrossRef]
44. Manini, I.; Ruaro, M.E.; Sgarra, R.; Bartolini, A.; Caponnetto, F.; Ius, T.; Skrap, M.; Di Loreto, C.; Beltrami, A.P.;
Manfioletti, G.; et al. Semaphorin-7A on Exosomes: A Promigratory Signal in the Glioma Microenvironment.
Cancers (Basel) 2019, 11, 758. [CrossRef]
45. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011,
17, 10–12. [CrossRef]
Biomedicines 2020, 8, 564 20 of 22
46. Kozomara, A.; Griffiths-Jones, S. miRBase: Integrating microRNA annotation and deep-sequencing data.
Nucleic Acids Res. 2011, 39, D152–D157. [CrossRef]
47. Trapnell, C.; Williams, B.A.; Pertea, G.; Mortazavi, A.; Kwan, G.; van Baren, M.J.; Salzberg, S.L.; Wold, B.J.;
Pachter, L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform
switching during cell differentiation. Nat. Biotechnol. 2010, 28, 511–515. [CrossRef]
48. Trapnell, C.; Hendrickson, D.G.; Sauvageau, M.; Goff, L.; Rinn, J.L.; Pachter, L. Differential analysis of gene
regulation at transcript resolution with RNA-seq. Nat. Biotechnol. 2013, 31, 46–53. [CrossRef]
49. Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. edgeR: A Bioconductor package for differential expression
analysis of digital gene expression data. Bioinformatics 2010, 26, 139–140. [CrossRef]
50. Vlachos, I.S.; Zagganas, K.; Paraskevopoulou, M.D.; Georgakilas, G.; Karagkouni, D.; Vergoulis, T.; Dalamagas, T.;
Hatzigeorgiou, A.G. DIANA-miRPath v3.0: Deciphering microRNA function with experimental support.
Nucleic Acids Res. 2015, 43, W460–W466. [CrossRef]
51. Quail, D.F.; Joyce, J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013,
19, 1423–1437. [CrossRef]
52. Sirko, S.; Behrendt, G.; Johansson, P.A.; Tripathi, P.; Costa, M.; Bek, S.; Heinrich, C.; Tiedt, S.; Colak, D.;
Dichgans, M.; et al. Reactive glia in the injured brain acquire stem cell properties in response to sonic
hedgehog. [corrected]. Cell Stem Cell 2013, 12, 426–439. [CrossRef]
53. Thery, C.; Amigorena, S.; Raposo, G.; Clayton, A. Isolation and characterization of exosomes from cell culture
supernatants and biological fluids. Curr. Protoc. Cell Biol. 2006, Chapter 3, Unit 3.22. [CrossRef]
54. Pigati, L.; Yaddanapudi, S.C.; Iyengar, R.; Kim, D.J.; Hearn, S.A.; Danforth, D.; Hastings, M.L.; Duelli, D.M.
Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS ONE
2010, 5, e13515. [CrossRef]
55. Guduric-Fuchs, J.; O’Connor, A.; Camp, B.; O’Neill, C.L.; Medina, R.J.; Simpson, D.A. Selective extracellular
vesicle-mediated export of an overlapping set of microRNAs from multiple cell types. BMC Genom. 2012, 13,
357. [CrossRef]
56. Jenjaroenpun, P.; Kremenska, Y.; Nair, V.M.; Kremenskoy, M.; Joseph, B.; Kurochkin, I.V. Characterization of
RNA in exosomes secreted by human breast cancer cell lines using next-generation sequencing. PeerJ 2013, 1,
e201. [CrossRef]
57. Batagov, A.O.; Kurochkin, I.V. Exosomes secreted by human cells transport largely mRNA fragments that
are enriched in the 3′-untranslated regions. Biol. Direct. 2013, 8, 12. [CrossRef]
58. Bolukbasi, M.F.; Mizrak, A.; Ozdener, G.B.; Madlener, S.; Strobel, T.; Erkan, E.P.; Fan, J.B.; Breakefield, X.O.;
Saydam, O. miR-1289 and “Zipcode”-like Sequence Enrich mRNAs in Microvesicles. Mol. Ther. Nucleic Acids
2012, 1, e10. [CrossRef]
59. Nabhan, J.F.; Hu, R.; Oh, R.S.; Cohen, S.N.; Lu, Q. Formation and release of arrestin domain-containing protein
1-mediated microvesicles (ARMMs) at plasma membrane by recruitment of TSG101 protein. Proc. Natl. Acad.
Sci. USA 2012, 109, 4146–4151. [CrossRef]
60. Wang, X.R.; Luo, H.; Li, H.L.; Cao, L.; Wang, X.F.; Yan, W.; Wang, Y.Y.; Zhang, J.X.; Jiang, T.; Kang, C.S.; et al.
Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN.
Neuro-Oncology 2013, 15, 1491–1501. [CrossRef]
61. Lee, S.T.; Chu, K.; Oh, H.J.; Im, W.S.; Lim, J.Y.; Kim, S.K.; Park, C.K.; Jung, K.H.; Lee, S.K.; Kim, M.; et al. Let-7
microRNA inhibits the proliferation of human glioblastoma cells. J. Neurooncol. 2011, 102, 19–24. [CrossRef]
62. Buonfiglioli, A.; Efe, I.E.; Guneykaya, D.; Ivanov, A.; Huang, Y.; Orlowski, E.; Kruger, C.; Deisz, R.A.;
Markovic, D.; Fluh, C.; et al. let-7 MicroRNAs Regulate Microglial Function and Suppress Glioma Growth
through Toll-Like Receptor 7. Cell Rep. 2019, 29, 3460–3471. [CrossRef]
63. Zhou, X.; Ren, Y.; Moore, L.; Mei, M.; You, Y.; Xu, P.; Wang, B.; Wang, G.; Jia, Z.; Pu, P.; et al. Downregulation
of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of
PTEN status. Lab. Investig. 2010, 90, 144–155. [CrossRef]
64. Sayed, D.; He, M.; Hong, C.; Gao, S.; Rane, S.; Yang, Z.; Abdellatif, M. MicroRNA-21 is a downstream
effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J. Biol. Chem. 2010, 285,
20281–20290. [CrossRef]
65. Zhang, C.; Kang, C.; You, Y.; Pu, P.; Yang, W.; Zhao, P.; Wang, G.; Zhang, A.; Jia, Z.; Han, L.; et al.
Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro
and in vivo. Int. J. Oncol. 2009, 34, 1653–1660. [CrossRef]
Biomedicines 2020, 8, 564 21 of 22
66. Zhang, J.; Han, L.; Ge, Y.; Zhou, X.; Zhang, A.; Zhang, C.; Zhong, Y.; You, Y.; Pu, P.; Kang, C. miR-221/222
promote malignant progression of glioma through activation of the Akt pathway. Int. J. Oncol. 2010, 36,
913–920. [CrossRef]
67. Gal, H.; Pandi, G.; Kanner, A.A.; Ram, Z.; Lithwick-Yanai, G.; Amariglio, N.; Rechavi, G.; Givol, D. MIR-451
and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem. Biophys. Res. Commun.
2008, 376, 86–90. [CrossRef]
68. Nan, Y.; Han, L.; Zhang, A.; Wang, G.; Jia, Z.; Yang, Y.; Yue, X.; Pu, P.; Zhong, Y.; Kang, C. MiRNA-451 plays a
role as tumor suppressor in human glioma cells. Brain Res. 2010, 1359, 14–21. [CrossRef]
69. Sakr, M.; Takino, T.; Sabit, H.; Nakada, M.; Li, Z.; Sato, H. miR-150-5p and miR-133a suppress glioma cell
proliferation and migration through targeting membrane-type-1 matrix metalloproteinase. Gene 2016, 587,
155–162. [CrossRef]
70. Qian, M.; Wang, S.; Guo, X.; Wang, J.; Zhang, Z.; Qiu, W.; Gao, X.; Chen, Z.; Xu, J.; Zhao, R.; et al. Hypoxic
glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting
TERF2IP via the STAT3 and NF-kappaB pathways. Oncogene 2020, 39, 428–442. [CrossRef]
71. Cui, T.; Bell, E.H.; McElroy, J.; Becker, A.P.; Gulati, P.M.; Geurts, M.; Mladkova, N.; Gray, A.; Liu, K.; Yang, L.;
et al. miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human
glioblastoma. Oncogene 2019, 38, 2923–2936. [CrossRef]
72. Lv, Q.L.; Zhu, H.T.; Li, H.M.; Cheng, X.H.; Zhou, H.H.; Chen, S.H. Down-regulation of miRNA-320c promotes
tumor growth and metastasis and predicts poor prognosis in human glioma. Brain Res. Bull. 2018, 139,
125–132. [CrossRef]
73. Pan, C.; Gao, H.; Zheng, N.; Gao, Q.; Si, Y.; Zhao, Y. MiR-320 inhibits the growth of glioma cells through
downregulating PBX3. Biol. Res. 2017, 50, 31. [CrossRef]
74. Li, T.; Ma, J.; Han, X.; Jia, Y.; Yuan, H.; Shui, S.; Guo, D. MicroRNA-320 Enhances Radiosensitivity of Glioma
Through Down-Regulation of Sirtuin Type 1 by Directly Targeting Forkhead Box Protein M1. Transl. Oncol.
2018, 11, 205–212. [CrossRef]
75. Han, L.; Li, Z.; Jiang, Y.; Jiang, Z.; Tang, L. SNHG29 regulates miR-223-3p/CTNND1 axis to promote
glioblastoma progression via Wnt/beta-catenin signaling pathway. Cancer Cell Int. 2019, 19, 345. [CrossRef]
76. Ji, Y.; Wei, Y.; Wang, J.; Gong, K.; Zhang, Y.; Zuo, H. Correlation of microRNA-10b upregulation and poor
prognosis in human gliomas. Tumour Biol. 2015, 36, 6249–6254. [CrossRef]
77. Li, W.; Li, C.; Xiong, Q.; Tian, X.; Ru, Q. MicroRNA-10b-5p downregulation inhibits the invasion of glioma
cells via modulating homeobox B3 expression. Exp. Ther. Med. 2019, 17, 4577–4585. [CrossRef]
78. Xue, J.; Zhou, A.; Wu, Y.; Morris, S.A.; Lin, K.; Amin, S.; Verhaak, R.; Fuller, G.; Xie, K.; Heimberger, A.B.; et al.
miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis. Cancer Res. 2016, 76, 4293–4304.
[CrossRef]
79. Li, J.; Yuan, H.; Xu, H.; Zhao, H.; Xiong, N. Hypoxic Cancer-Secreted Exosomal miR-182-5p Promotes
Glioblastoma Angiogenesis by Targeting Kruppel-like Factor 2 and 4. Mol. Cancer Res. 2020, 18, 1218–1231.
[CrossRef]
80. Yu, H.; Zheng, J.; Liu, X.; Xue, Y.; Shen, S.; Zhao, L.; Li, Z.; Liu, Y. Transcription Factor NFAT5 Promotes
Glioblastoma Cell-driven Angiogenesis via SBF2-AS1/miR-338-3p-Mediated EGFL7 Expression Change.
Front. Mol. Neurosci. 2017, 10, 301. [CrossRef]
81. Wang, W.Y.; Lu, W.C. Reduced Expression of hsa-miR-338-3p Contributes to the Development of Glioma
Cells by Targeting Mitochondrial 3-Oxoacyl-ACP Synthase (OXSM) in Glioblastoma (GBM). OncoTargets
Ther. 2020, 13, 9513–9523. [CrossRef] [PubMed]
82. Xia, Z.; Liu, F.; Zhang, J.; Liu, L. Decreased Expression of MiRNA-204-5p Contributes to Glioma Progression
and Promotes Glioma Cell Growth, Migration and Invasion. PLoS ONE 2015, 10, e0132399. [CrossRef]
[PubMed]
83. Li, Y.; Li, Y.; Ge, P.; Ma, C. MiR-126 Regulates the ERK Pathway via Targeting KRAS to Inhibit the Glioma
Cell Proliferation and Invasion. Mol. Neurobiol. 2017, 54, 137–145. [CrossRef] [PubMed]
84. Ahn, S.H.; Ahn, J.H.; Ryu, D.R.; Lee, J.; Cho, M.S.; Choi, Y.H. Effect of Necrosis on the miRNA-mRNA
Regulatory Network in CRT-MG Human Astroglioma Cells. Cancer Res. Treat. 2018, 50, 382–397. [CrossRef]
[PubMed]
Biomedicines 2020, 8, 564 22 of 22
85. Ames, H.M.; Yuan, M.; Vizcaino, M.A.; Yu, W.; Rodriguez, F.J. MicroRNA profiling of low-grade glial and
glioneuronal tumors shows an independent role for cluster 14q32.31 member miR-487b. Mod. Pathol. 2017,
30, 204–216. [CrossRef] [PubMed]
86. Wade, A.; Robinson, A.E.; Engler, J.R.; Petritsch, C.; James, C.D.; Phillips, J.J. Proteoglycans and their roles in
brain cancer. FEBS J. 2013, 280, 2399–2417. [CrossRef]
87. Steck, P.A.; Moser, R.P.; Bruner, J.M.; Liang, L.; Freidman, A.N.; Hwang, T.L.; Yung, W.K. Altered expression
and distribution of heparan sulfate proteoglycans in human gliomas. Cancer Res. 1989, 49, 2096–2103.
88. Atukeren, P.; Kunbaz, A.; Turk, O.; Kemerdere, R.; Ulu, M.O.; Turkmen Inanir, N.; Tanriverdi, T. Expressions
of Endocan in Patients with Meningiomas and Gliomas. Dis. Markers 2016, 2016, 7157039. [CrossRef]
89. Yoshida, T.; Matsuda, Y.; Naito, Z.; Ishiwata, T. CD44 in human glioma correlates with histopathological
grade and cell migration. Pathol. Int. 2012, 62, 463–470. [CrossRef]
90. Song, L.; Liu, L.; Wu, Z.; Li, Y.; Ying, Z.; Lin, C.; Wu, J.; Hu, B.; Cheng, S.Y.; Li, M.; et al. TGF-beta induces
miR-182 to sustain NF-kappaB activation in glioma subsets. J. Clin. Investig. 2012, 122, 3563–3578. [CrossRef]
91. Huang, B.S.; Luo, Q.Z.; Han, Y.; Li, X.B.; Cao, L.J.; Wu, L.X. microRNA-223 promotes the growth and invasion
of glioblastoma cells by targeting tumor suppressor PAX6. Oncol. Rep. 2013, 30, 2263–2269. [CrossRef]
92. Villain, G.; Poissonnier, L.; Noueihed, B.; Bonfils, G.; Rivera, J.C.; Chemtob, S.; Soncin, F.; Mattot, V.
miR-126-5p promotes retinal endothelial cell survival through SetD5 regulation in neurons. Development
2018, 145. [CrossRef]
93. Gao, H.; Zhao, H.; Xiang, W. Expression level of human miR-34a correlates with glioma grade and prognosis.
J. Neurooncol. 2013, 113, 221–228. [CrossRef]
94. Li, Y.; Guessous, F.; Zhang, Y.; Dipierro, C.; Kefas, B.; Johnson, E.; Marcinkiewicz, L.; Jiang, J.; Yang, Y.;
Schmittgen, T.D.; et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.
Cancer Res. 2009, 69, 7569–7576. [CrossRef]
95. Duan, J.; Zhou, K.; Tang, X.; Duan, J.; Zhao, L. MicroRNA-34a inhibits cell proliferation and induces cell
apoptosis of glioma cells via targeting of Bcl-2. Mol. Med. Rep. 2016, 14, 432–438. [CrossRef]
96. Li, Q.; Wang, C.; Cai, L.; Lu, J.; Zhu, Z.; Wang, C.; Su, Z.; Lu, X. miR34a derived from mesenchymal stem
cells stimulates senescence in glioma cells by inducing DNA damage. Mol. Med. Rep. 2019, 19, 1849–1857.
[CrossRef]
97. Feng, F.; Kuai, D.; Wang, H.; Li, T.; Miao, W.; Liu, Y.; Fan, Y. Reduced expression of microRNA-497 is
associated with greater angiogenesis and poor prognosis in human gliomas. Hum. Pathol. 2016, 58, 47–53.
[CrossRef]
98. Lu, F.; Ye, Y.; Zhang, H.; He, X.; Sun, X.; Yao, C.; Mao, H.; He, X.; Qian, C.; Wang, B.; et al. miR-497/Wnt3a/c-jun
feedback loop regulates growth and epithelial-to-mesenchymal transition phenotype in glioma cells. Int. J.
Biol. Macromol. 2018, 120, 985–991. [CrossRef]
99. Ngiow, S.F.; Young, A. Re-education of the Tumor Microenvironment With Targeted Therapies and
Immunotherapies. Front. Immunol. 2020, 11, 1633. [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
